SOUTH SAN FRANCISCO, Calif., May 18, 2026
Genentech, a member of the Roche Group, announced that it will present major new oncology data at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2, reinforcing the growing potential of investigational oral SERD giredestrant to reshape treatment strategies in ER-positive/HER2-negative breast cancer. The company will showcase data from more than 15 cancer indications involving nine approved and investigational medicines spanning breast cancer, blood cancer, lung cancer, gastrointestinal cancer, and bladder cancer. The presentations highlight Genentech’s continued investment in precision oncology, antibody-drug conjugates, bispecific antibodies, and brain-penetrant therapies designed to address some of the most difficult-to-treat cancers.
Giredestrant Takes Center Stage in Breast Cancer Program
Genentech’s ASCO 2026 oncology program is heavily focused on giredestrant, an investigational oral selective estrogen receptor degrader (SERD) being studied across early and advanced stages of ER-positive, HER2-negative breast cancer, a subtype representing nearly 70% of all breast cancer diagnoses. New findings from the pivotal Phase III lidERA Breast Cancer study will evaluate whether the previously reported 30% reduction in invasive disease recurrence or death remains consistent across both premenopausal and postmenopausal patient populations. The company confirmed that the lidERA data package has already been submitted to the U.S. FDA, strengthening expectations that giredestrant could emerge as a future standard endocrine therapy in early-stage breast cancer.
Additional results from the Phase III persevERA Breast Cancer study will examine giredestrant combined with palbociclib as a first-line treatment for advanced or metastatic disease. While the trial did not meet its primary endpoint, Genentech stated the combination still demonstrated a numerical improvement in progression-free survival, suggesting promising activity in endocrine-sensitive metastatic settings. Further analyses from the evERA Breast Cancer trial will also be presented, highlighting sustained clinical benefit for patients receiving giredestrant plus everolimus after prior CDK4/6 inhibitor therapy. Genentech recently received FDA acceptance of its New Drug Application based on positive evERA findings, marking another important regulatory milestone for the program.
New HER2, Lung Cancer and Blood Cancer Data Expand Pipeline Visibility
Beyond giredestrant, Genentech will unveil new data targeting HER2-positive metastatic breast cancer, including preliminary Phase Ic expansion results for ZN-A-1041, a highly brain-permeable HER2-selective tyrosine kinase inhibitor designed to improve treatment of brain metastases. The molecule is being studied in combination with other HER2-targeted therapies, including trastuzumab deruxtecan and pertuzumab-trastuzumab combinations. Brain metastases remain one of the biggest challenges in advanced HER2-positive disease, making the development of brain-penetrant therapies an increasingly important focus area across oncology.
Advertisement
In lung cancer, Genentech will present findings from the Krascendo-170 study evaluating divarasib, a next-generation oral KRAS G12C inhibitor, in combination with pembrolizumab for first-line treatment of advanced non-small cell lung cancer. The data helped inform the ongoing Phase III Krascendo 2 program investigating chemotherapy-free approaches regardless of PD-L1 status. The company will also highlight updated Phase III SUNMO trial results evaluating Lunsumio plus Polivy in relapsed or refractory diffuse large B-cell lymphoma, aiming to establish a fixed-duration, chemotherapy-free treatment option for patients ineligible for transplant. Additional presentations will feature therapies including Columvi, Tecentriq, Itovebi, and Kadcyla, further demonstrating Genentech’s broad oncology pipeline spanning solid tumors and hematologic malignancies.
ASCO 2026 Data Reinforces Genentech’s Oncology Expansion Strategy
According to Genentech Chief Medical Officer Levi Garraway, M.D., Ph.D., the ASCO 2026 presentations reflect the company’s strategy of targeting cancers with the highest patient burden while advancing therapies capable of improving long-term outcomes in difficult clinical settings. The breadth of data being presented — ranging from SERDs and KRAS inhibitors to bispecific antibodies and antibody-drug conjugates — highlights Genentech’s growing emphasis on combining targeted precision medicine with next-generation immuno-oncology technologies.
The company’s oncology portfolio continues to evolve as competition intensifies across the global cancer therapeutics market, particularly in breast cancer where companies are racing to develop more effective endocrine therapies capable of overcoming resistance mechanisms. With pivotal data updates, ongoing regulatory submissions, and multiple late-stage studies underway, Genentech’s ASCO 2026 presence positions the company as one of the major drivers shaping the future of cancer treatment innovation.
Source: Genentech, Roche press release
